Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
 2016 World Congress - EconoTimes)
BURLINGTON, Mass., April 01, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
The presentation will be part of Concurrent Session 9 - OA Treatment - Structure and Pain with abstract presentations. The title of the scientific abstract is “Sustained and Profound Analgesic Benefits in People with Osteoarthritis of the Knee Using FX006, an Intra-articular Extended-Release Formulation of Triamcinolone Acetonide.”
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
